GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Net Income Including Noncontrolling Interests

Orthocell (ASX:OCC) Net Income Including Noncontrolling Interests : A$-7.18 Mil (TTM As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Orthocell Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Orthocell's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2024 was A$-1.95 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 was A$-7.18 Mil.

Orthocell Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Orthocell's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Net Income Including Noncontrolling Interests Chart

Orthocell Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.15 -9.04 -9.11 -6.25 -7.18

Orthocell Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.45 -4.06 -2.19 -5.23 -1.95

Orthocell Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthocell Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Orthocell's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Orthocell Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:ADO ASX:DXB ASX:SPL ASX:ALA ASX:BIT ASX:PTX ASX:RCE ASX:ACW ASX:RAD ASX:AGN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Website
https://www.orthocell.com.au
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.